Radiation Oncology Research Center (RORC), Cancer Institute, Imam Khomeini Hospital complex, Tehran University of Medical Sciences, Tehran, Iran; Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Brachytherapy. 2022 Jul-Aug;21(4):494-500. doi: 10.1016/j.brachy.2022.03.005. Epub 2022 May 2.
Rhabdomyosarcoma (RMS) is the most common pediatric soft-tissue sarcoma, mostly involving the genitourinary (GU) tract, head and neck, and extremities. This study reports the long-term outcome of two infants with recurrent GU-RMS who underwent combination therapy with chemotherapy (ChT) and salvage brachytherapy (BT).
An 18-month-old girl with vaginal bleeding and a 7-month-old boy with urinary retention presented with a diagnosis of vaginal, and bladder/prostate embryonal RMS, respectively. Surgical resection and ChT were done for both patients. However, both developed local recurrences after one year and subsequently, underwent second-line ChT and salvage interstitial high dose rate BT.
The clinical target volumes for the first and second patients were treated to a totaldose of 32 Gy in 10 fractions and 35 Gy in 10 fractions, respectively, with two fractions delivered per day with a 6-h interval between fractions. After 9 years of follow-up, both patients are alive with natural growth and no late complication or evidence of recurrence.
Our report shows that BT (for patients with no prior history of irradiation) could result in long-term disease-free survival in well-selected pediatric patients with recurrent GU embryonal RMS without inflicting expected adverse effects of external beam radiotherapy.
横纹肌肉瘤(RMS)是最常见的小儿软组织肉瘤,主要涉及泌尿生殖系统(GU)、头颈部和四肢。本研究报告了两名接受化疗(ChT)联合挽救性近距离放疗(BT)治疗复发性 GU-RMS 的婴儿的长期结果。
一名 18 个月大的女孩因阴道出血,一名 7 个月大的男孩因尿潴留就诊,分别诊断为阴道和膀胱/前列腺胚胎性 RMS。两名患者均接受了手术切除和 ChT,但均在一年后出现局部复发,随后接受二线 ChT 和挽救性间质高剂量率 BT。
第一和第二例患者的临床靶区分别接受了总剂量为 32 Gy/10 次和 35 Gy/10 次的治疗,每天两次,两次之间间隔 6 小时。随访 9 年后,两名患者均存活,生长自然,无晚期并发症或复发迹象。
我们的报告表明,对于没有既往放疗史的患者,BT(对于没有既往放疗史的患者)可能导致复发性 GU 胚胎性 RMS 患儿长期无病生存,而不会产生外照射放疗的预期不良反应。